{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T15:37:05Z","timestamp":1777649825767,"version":"3.51.4"},"reference-count":63,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T00:00:00Z","timestamp":1698278400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Endocrine"],"DOI":"10.1007\/s12020-023-03573-7","type":"journal-article","created":{"date-parts":[[2023,10,26]],"date-time":"2023-10-26T19:01:40Z","timestamp":1698346900000},"page":"527-536","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["Epidemiology and diagnosis of primary aldosteronism. What have we learned from the SPAIN-ALDO registry?"],"prefix":"10.1007","volume":"83","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0519-0072","authenticated-orcid":false,"given":"Marta","family":"Araujo-Castro","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eider","family":"Pascual-Corrales","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Patricia","family":"Mart\u00edn Rojas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0310-7095","authenticated-orcid":false,"given":"Paola","family":"Parra Ram\u00edrez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,10,26]]},"reference":[{"key":"3573_CR1","doi-asserted-by":"publisher","first-page":"876","DOI":"10.1016\/S2213-8587(21)00210-2","volume":"9","author":"M Reincke","year":"2021","unstructured":"M. Reincke, I. Bancos, P. Mulatero, U.I. Scholl, M. Stowasser, T.A. Williams, Diagnosis and treatment of primary aldosteronism. Lancet Diabetes Endocrinol. 9, 876\u2013892 (2021). https:\/\/doi.org\/10.1016\/S2213-8587(21)00210-2","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3573_CR2","doi-asserted-by":"publisher","first-page":"1919","DOI":"10.1097\/HJH.0000000000002510","volume":"38","author":"P Mulatero","year":"2020","unstructured":"P. Mulatero, S. Monticone, J. Deinum, L. Amar, A. Prejbisz, M.C. Zennaro et al. Genetics, prevalence, screening and confirmation of primary aldosteronism: a position statement and consensus of the Working Group on Endocrine Hypertension of The European Society of Hypertension. J. Hypertens. 38, 1919\u20131928 (2020). https:\/\/doi.org\/10.1097\/HJH.0000000000002510","journal-title":"J. Hypertens."},{"key":"3573_CR3","doi-asserted-by":"publisher","first-page":"2293","DOI":"10.1016\/j.jacc.2006.07.059","volume":"48","author":"GP Rossi","year":"2006","unstructured":"G.P. Rossi, G. Bernini, C. Caliumi, G. Desideri, B. Fabris, C. Ferri et al. A Prospective Study of the Prevalence of Primary Aldosteronism in 1,125 Hypertensive Patients. J. Am. Coll. Cardiol. 48, 2293\u20132300 (2006). https:\/\/doi.org\/10.1016\/j.jacc.2006.07.059","journal-title":"J. Am. Coll. Cardiol."},{"key":"3573_CR4","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1038\/S41574-022-00730-2","volume":"18","author":"AF Turcu","year":"2022","unstructured":"A.F. Turcu, J. Yang, A. Vaidya, Primary aldosteronism - a multidimensional syndrome. Nat. Rev. Endocrinol. 18, 665\u2013682 (2022). https:\/\/doi.org\/10.1038\/S41574-022-00730-2","journal-title":"Nat. Rev. Endocrinol."},{"key":"3573_CR5","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1161\/HYPERTENSIONAHA.119.14063","volume":"75","author":"J Burrello","year":"2020","unstructured":"J. Burrello, S. Monticone, I. Losano, G. Cavagli\u00e0, F. Buffolo, M. Tetti et al. Prevalence of hypokalemia and primary aldosteronism in 5100 patients referred to a tertiary hypertension unit. Hypertension 75, 1025\u20131033 (2020). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14063","journal-title":"Hypertension"},{"key":"3573_CR6","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S2213-8587(17)30319-4","volume":"6","author":"S Monticone","year":"2018","unstructured":"S. Monticone, F. D\u2019Ascenzo, C. Moretti, T.A. Williams, F. Veglio, F. Gaita et al. Cardiovascular events and target organ damage in primary aldosteronism compared with essential hypertension: a systematic review and meta-analysis. Lancet Diabetes Endocrinol. 6, 41\u201350 (2018). https:\/\/doi.org\/10.1016\/S2213-8587(17)30319-4","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3573_CR7","doi-asserted-by":"publisher","first-page":"4826","DOI":"10.1210\/jc.2013-2805","volume":"98","author":"P Mulatero","year":"2013","unstructured":"P. Mulatero, S. Monticone, C. Bertello, A. Viola, D. Tizzani, A. Iannaccone et al. Long-Term cardio- and cerebrovascular events in patients with primary aldosteronism. J. Clin. Endocrinol. Metab. 98, 4826\u20134833 (2013). https:\/\/doi.org\/10.1210\/jc.2013-2805","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR8","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1161\/HYPERTENSIONAHA.113.01060","volume":"62","author":"S Savard","year":"2013","unstructured":"S. Savard, L. Amar, P.F. Plouin, O. Steichen, Cardiovascular complications associated with primary aldosteronism: A controlled cross-sectional study. Hypertension 62, 331\u2013336 (2013). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.113.01060","journal-title":"Hypertension"},{"key":"3573_CR9","doi-asserted-by":"publisher","first-page":"1889","DOI":"10.1210\/jc.2015-4061","volume":"101","author":"JW Funder","year":"2016","unstructured":"J.W. Funder, R.M. Carey, F. Mantero, M.H. Murad, M. Reincke, H. Shibata et al. The management of primary aldosteronism: Case detection, diagnosis, and treatment: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 101, 1889\u20131916 (2016). https:\/\/doi.org\/10.1210\/jc.2015-4061","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR10","doi-asserted-by":"publisher","unstructured":"M. Araujo-Castro, P. Parra-Ram\u00edrez, Diagnosis of primary hyperaldosteronism. Med. Clin. (Barc) (2021) https:\/\/doi.org\/10.1016\/j.medcli.2021.10.012","DOI":"10.1016\/j.medcli.2021.10.012"},{"key":"3573_CR11","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1016\/j.medcli.2020.04.029","volume":"155","author":"M Araujo-Castro","year":"2020","unstructured":"M. Araujo-Castro, Treatment of primary hyperaldosteronism. Med. Clin. (Barc.) 155, 302\u2013308 (2020). https:\/\/doi.org\/10.1016\/j.medcli.2020.04.029","journal-title":"Med. Clin. (Barc.)"},{"key":"3573_CR12","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1136\/bmj.2.6035.554","volume":"2","author":"G Berglund","year":"1976","unstructured":"G. Berglund, O. Andersson, L. Wilhelmsen, Prevalence of primary and secondary hypertension: Studies in a random population sample. Br. Med. J. 2, 554\u2013556 (1976). https:\/\/doi.org\/10.1136\/bmj.2.6035.554","journal-title":"Br. Med. J."},{"key":"3573_CR13","doi-asserted-by":"publisher","first-page":"1589","DOI":"10.1001\/archinte.1981.00340130033011","volume":"141","author":"K Hiramatsu","year":"1981","unstructured":"K. Hiramatsu, T. Yamada, Y. Yukimura, I. Komiya, K. Ichikawa, M. Ishihara et al. A Screening Test to Identify Aldosterone-Producing Adenoma by Measuring Plasma Renin Activity: Results in Hypertensive Patients. Arch. Intern. Med. 141, 1589\u20131593 (1981). https:\/\/doi.org\/10.1001\/archinte.1981.00340130033011","journal-title":"Arch. Intern. Med."},{"key":"3573_CR14","doi-asserted-by":"publisher","unstructured":"S.C. K\u00e4yser, T. Dekkers, H.J. Groenewoud, G.J. Van Der Wilt, J. Carel Bakx, M.C. Van Der Wel, et al. Study heterogeneity and estimation of prevalence of primary aldosteronism: a systematic review and meta-regression analysis. J. Clin. Endocrinol. Metab. 101 (2016) https:\/\/doi.org\/10.1210\/jc.2016-1472","DOI":"10.1210\/jc.2016-1472"},{"key":"3573_CR15","doi-asserted-by":"publisher","first-page":"1811","DOI":"10.1016\/j.jacc.2017.01.052","volume":"69","author":"S Monticone","year":"2017","unstructured":"S. Monticone, J. Burrello, D. Tizzani, C. Bertello, A. Viola, F. Buffolo et al. Prevalence and Clinical Manifestations of Primary Aldosteronism Encountered in Primary Care Practice. J. Am. Coll. Cardiol. 69, 1811\u20131820 (2017). https:\/\/doi.org\/10.1016\/j.jacc.2017.01.052","journal-title":"J. Am. Coll. Cardiol."},{"key":"3573_CR16","doi-asserted-by":"publisher","first-page":"408","DOI":"10.1016\/j.endinu.2020.03.002","volume":"67","author":"M Araujo-Castro","year":"2020","unstructured":"M. Araujo-Castro, M. Iturregui Guevara, M. Calatayud Guti\u00e9rrez, P. Parra Ram\u00edrez, P. Gracia Gimeno, F.A. Hanzu et al. Practical guide on the initial evaluation, follow-up, and treatment of adrenal incidentalomas Adrenal Diseases Group of the Spanish Society of Endocrinology and Nutrition. Endocrinol. Diabetes y. Nutr. 67, 408\u2013419 (2020). https:\/\/doi.org\/10.1016\/j.endinu.2020.03.002","journal-title":"Endocrinol. Diabetes y. Nutr."},{"key":"3573_CR17","doi-asserted-by":"publisher","first-page":"3266","DOI":"10.1210\/jc.2008-0104","volume":"93","author":"JW Funder","year":"2008","unstructured":"J.W. Funder, R.M. Carey, C. Fardella, C.E. Gomez-Sanchez, F. Mantero, M. Stowasser et al. Case detection, diagnosis, and treatment of patients with primary aldosteronism: An endocrine society clinical practice guideline. J. Clin. Endocrinol. Metab. 93, 3266\u20133281 (2008). https:\/\/doi.org\/10.1210\/jc.2008-0104","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR18","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/J.ENDIEN.2022.01.013","volume":"70","author":"P Parra Ram\u00edrez","year":"2023","unstructured":"P. Parra Ram\u00edrez, P. Mart\u00edn Rojas-Marcos, M. Cuesta Hern\u00e1ndez, J.G. Ruiz-S\u00e1nchez, C. Lamas Oliveira, F.A. Hanzu et al. First survey on the diagnosis and treatment of primary aldosteronism by Spanish Endocrinology and Nutrition specialists. Endocrinol. Diabetes y. Nutr. 70, 374\u2013380 (2023). https:\/\/doi.org\/10.1016\/J.ENDIEN.2022.01.013","journal-title":"Endocrinol. Diabetes y. Nutr."},{"key":"3573_CR19","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/1470320310366581","volume":"11","author":"A Di Murro","year":"2010","unstructured":"A. Di Murro, L. Petramala, D. Cotesta, L. Zinnamosca, E. Crescenzi, C. Marinelli et al. Renin-angiotensin-aldosterone system in patients with sleep apnoea: Prevalence of primary aldosteronism. J. Renin-Angiotensin-Aldosterone Syst. 11, 165\u2013172 (2010). https:\/\/doi.org\/10.1177\/1470320310366581","journal-title":"J. Renin-Angiotensin-Aldosterone Syst."},{"key":"3573_CR20","doi-asserted-by":"publisher","first-page":"1532","DOI":"10.1161\/HYPERTENSIONAHA.119.13833","volume":"74","author":"F Buffolo","year":"2019","unstructured":"F. Buffolo, Q. Li, S. Monticone, D.A. Heinrich, A. Mattei, J. Pieroni et al. Primary aldosteronism and obstructive sleep apnea a cross-sectional multi-ethnic study. Hypertension 74, 1532\u20131540 (2019). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.13833","journal-title":"Hypertension"},{"key":"3573_CR21","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1097\/HJH.0000000000002250","volume":"38","author":"TM Seccia","year":"2020","unstructured":"T.M. Seccia, C. Letizia, M.L. Muiesan, S. Lerco, M. Cesari, V. Bisogni et al. Atrial fibrillation as presenting sign of primary aldosteronism: results of the Prospective Appraisal on the Prevalence of Primary Aldosteronism in Hypertensive (PAPPHY) Study. J. Hypertens. 38, 332\u2013339 (2020). https:\/\/doi.org\/10.1097\/HJH.0000000000002250","journal-title":"J. Hypertens."},{"key":"3573_CR22","doi-asserted-by":"publisher","first-page":"1409","DOI":"10.1210\/jc.2012-3353","volume":"98","author":"A Markou","year":"2013","unstructured":"A. Markou, T. Pappa, G. Kaltsas, A. Gouli, K. Mitsakis, P. Tsounas et al. Evidence of primary aldosteronism in a predominantly female cohort of normotensive individuals: A very high odds ratio for progression into arterial hypertension. J. Clin. Endocrinol. Metab. 98, 1409\u20131416 (2013). https:\/\/doi.org\/10.1210\/jc.2012-3353","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR23","doi-asserted-by":"publisher","first-page":"950","DOI":"10.1161\/HYPERTENSIONAHA.116.08952","volume":"69","author":"R Baudrand","year":"2017","unstructured":"R. Baudrand, F.J. Guarda, C. Fardella, G. Hundemer, J. Brown, G. Williams et al. Continuum of Renin-Independent Aldosteronism in Normotension. Hypertension 69, 950\u2013956 (2017). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.116.08952","journal-title":"Hypertension"},{"key":"3573_CR24","doi-asserted-by":"publisher","first-page":"10","DOI":"10.7326\/M20-0065","volume":"173","author":"JM Brown","year":"2020","unstructured":"J.M. Brown, M. Siddiqui, D.A. Calhoun, R.M. Carey, P.N. Hopkins, G.H. Williams et al. The unrecognized prevalence of primary aldosteronism a cross-sectional study. Ann. Intern. Med. 173, 10\u201320 (2020). https:\/\/doi.org\/10.7326\/M20-0065","journal-title":"Ann. Intern. Med."},{"key":"3573_CR25","doi-asserted-by":"publisher","first-page":"1188","DOI":"10.1016\/j.bbadis.2010.08.005","volume":"1802","author":"JW Funder","year":"2010","unstructured":"J.W. Funder, M. Reincke, Aldosterone: A cardiovascular risk factor? Biochim. Biophys. Acta - Mol. Basis Dis. 1802, 1188\u20131192 (2010). https:\/\/doi.org\/10.1016\/j.bbadis.2010.08.005","journal-title":"Biochim. Biophys. Acta - Mol. Basis Dis."},{"key":"3573_CR26","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1161\/HYPERTENSIONAHA.107.095448","volume":"50","author":"C Catena","year":"2007","unstructured":"C. Catena, G. Colussi, R. Lapenna, E. Nadalini, A. Chiuch, P. Gianfagna et al. Long-term cardiac effects of adrenalectomy or mineralocorticoid antagonists in patients with primary aldosteronism. Hypertension 50, 911\u2013918 (2007). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.107.095448","journal-title":"Hypertension"},{"key":"3573_CR27","doi-asserted-by":"publisher","first-page":"1243","DOI":"10.1016\/j.jacc.2005.01.015","volume":"45","author":"P Milliez","year":"2005","unstructured":"P. Milliez, X. Girerd, P.F. Plouin, J. Blacher, M.E. Safar, J.J. Mourad et al. Evidence for an increased rate of cardiovascular events in patients with primary aldosteronism. J. Am. Coll. Cardiol. 45, 1243\u20131248 (2005). https:\/\/doi.org\/10.1016\/j.jacc.2005.01.015","journal-title":"J. Am. Coll. Cardiol."},{"key":"3573_CR28","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1161\/HYPERTENSIONAHA.112.197111","volume":"60","author":"M Reincke","year":"2012","unstructured":"M. Reincke, E. Fischer, S. Gerum, K. Merkle, S. Schulz, A. Pallauf et al. Observational study mortality in treated primary aldosteronism: The German conn\u2019s registry. Hypertension 60, 618\u2013624 (2012). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.112.197111","journal-title":"Hypertension"},{"key":"3573_CR29","doi-asserted-by":"publisher","first-page":"439","DOI":"10.1007\/s12020-021-02704-2","volume":"73","author":"M Fern\u00e1ndez-Arg\u00fceso","year":"2021","unstructured":"M. Fern\u00e1ndez-Arg\u00fceso, E. Pascual-Corrales, N. Bengoa Rojano, A. Garc\u00eda Cano, L. Jim\u00e9nez Mendiguch\u00eda, M. Araujo-Castro, Higher risk of chronic kidney disease and progressive kidney function impairment in primary aldosteronism than in essential hypertension. Case-control study. Endocrine 73, 439\u2013446 (2021). https:\/\/doi.org\/10.1007\/s12020-021-02704-2","journal-title":"Endocrine"},{"key":"3573_CR30","doi-asserted-by":"publisher","unstructured":"M. Araujo-Castro, M. Paja Fano, B. Pla Peris, M. Gonz\u00e1lez Boillos, E. Pascual-Corrales, A. Garc\u00eda-Cano, et al. Autonomous cortisol secretion in patients with primary aldosteronism: prevalence and implications regarding cardiometabolic profile and surgical outcomes. Endocr. Connect. (2023) https:\/\/doi.org\/10.1530\/EC-23-0043","DOI":"10.1530\/EC-23-0043"},{"key":"3573_CR31","doi-asserted-by":"publisher","unstructured":"H.H. Loh, N. Sukor, Associations between primary aldosteronism and diabetes, poor bone health, and sleep apnea\u2014what do we know so far? J. Hum. Hypertens. 34 (2020) https:\/\/doi.org\/10.1038\/s41371-019-0294-8","DOI":"10.1038\/s41371-019-0294-8"},{"key":"3573_CR32","doi-asserted-by":"publisher","unstructured":"S. Shi, C. Lu, H. Tian, Y. Ren, T. Chen Primary Aldosteronism and Bone Metabolism: A Systematic Review and Meta-Analysis. Front. Endocrinol. (Lausanne) 11 (2020) https:\/\/doi.org\/10.3389\/fendo.2020.574151","DOI":"10.3389\/fendo.2020.574151"},{"key":"3573_CR33","doi-asserted-by":"publisher","unstructured":"M. Araujo-Castro, E. Pascual-Corrales, M. Fern\u00e1ndez-Arg\u00fceso, N. Bengoa-Rojano, A. Garc\u00eda Cano, L. Jim\u00e9nez Mendiguch\u00eda, et al. The prevalence of primary and secondary hyperparathyroidism and its cardiometabolic implications in primary aldosteronism. Minerva Endocrinol. (2023) https:\/\/doi.org\/10.23736\/S2724-6507.23.03866-6","DOI":"10.23736\/S2724-6507.23.03866-6"},{"key":"3573_CR34","doi-asserted-by":"publisher","first-page":"3771","DOI":"10.1210\/CLINEM\/DGAA606","volume":"105","author":"A Vaidya","year":"2020","unstructured":"A. Vaidya, R.M. Carey, Evolution of the Primary Aldosteronism Syndrome: Updating the Approach. J. Clin. Endocrinol. Metab. 105, 3771\u20133783 (2020). https:\/\/doi.org\/10.1210\/CLINEM\/DGAA606","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR35","doi-asserted-by":"publisher","first-page":"E53","DOI":"10.1161\/HYP.0000000000000084","volume":"72","author":"RM Carey","year":"2018","unstructured":"R.M. Carey, D.A. Calhoun, G.L. Bakris, R.D. Brook, S.L. Daugherty, C.R. Dennison-Himmelfarb et al. Resistant Hypertension: Detection, Evaluation, and Management: A Scientific Statement From the American Heart Association. Hypertens. (Dallas, Tex. 1979) 72, E53\u2013E90 (2018). https:\/\/doi.org\/10.1161\/HYP.0000000000000084","journal-title":"Hypertens. (Dallas, Tex. 1979)"},{"key":"3573_CR36","doi-asserted-by":"publisher","unstructured":"G.P. Rossi, V. Bisogni, A.V. Bacca, A. Belfiore, M. Cesari, A. Concistr\u00e8, et al. The 2020 Italian Society of Arterial Hypertension (SIIA) practical guidelines for the management of primary aldosteronism. Int. J. Cardiol. Hypertens. 5, (2020) https:\/\/doi.org\/10.1016\/j.ijchy.2020.100029","DOI":"10.1016\/j.ijchy.2020.100029"},{"key":"3573_CR37","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1161\/HYPERTENSIONAHA.119.14359","volume":"75","author":"G Jaffe","year":"2020","unstructured":"G. Jaffe, Z. Gray, G. Krishnan, M. Stedman, Y. Zheng, J. Han et al. Screening Rates for Primary Aldosteronism in Resistant Hypertension: A Cohort Study. Hypertens. (Dallas, Tex. 1979) 75, 650\u2013659 (2020). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.119.14359","journal-title":"Hypertens. (Dallas, Tex. 1979)"},{"key":"3573_CR38","doi-asserted-by":"publisher","unstructured":"M. Araujo-Castro, M. Paja Fano, B. Pla Peris, M. Gonz\u00e1lez Boillos, E. Pascual-Corrales, A.M. Garc\u00eda Cano, et al. Prevalence, risk factors and evolution of diabetes mellitus after treatment in primary aldosteronism. Results from the SPAIN-ALDO registry. J. Endocrinol. Investig. (2023) https:\/\/doi.org\/10.1007\/S40618-023-02090-8","DOI":"10.1007\/S40618-023-02090-8"},{"key":"3573_CR39","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1210\/jc.2005-1733","volume":"91","author":"F Fallo","year":"2006","unstructured":"F. Fallo, F. Veglio, C. Bertello, N. Sonino, P. Della Mea, M. Ermani et al. Prevalence and characteristics of the metabolic syndrome in primary aldosteronism. J. Clin. Endocrinol. Metab. 91, 454\u2013459 (2006). https:\/\/doi.org\/10.1210\/jc.2005-1733","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR40","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1055\/s-0029-1246189","volume":"42","author":"M Reincke","year":"2010","unstructured":"M. Reincke, C. Meisinger, R. Holle, M. Quinkler, S. Hahner, F. Beuschlein et al. Is primary aldosteronism associated with diabetes mellitus? Results of the German Conn\u2019s registry. Horm. Metab. Res 42, 435\u2013439 (2010). https:\/\/doi.org\/10.1055\/s-0029-1246189","journal-title":"Horm. Metab. Res"},{"issue":"Suppl 1","key":"3573_CR41","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/S0025-7753(17)30618-8","volume":"147","author":"J Franch Nadal","year":"2016","unstructured":"J. Franch Nadal, M. Mata Cases, D. Mauricio Puente, Epidemiology and clinical management of type 2 diabetes mellitus and associated comorbidities in Spain (e-Management study). Med Clin. (Barc.) 147(Suppl 1), 1\u20137 (2016). https:\/\/doi.org\/10.1016\/S0025-7753(17)30618-8","journal-title":"Med Clin. (Barc.)"},{"key":"3573_CR42","doi-asserted-by":"publisher","first-page":"1441","DOI":"10.1515\/CCLM-2015-1094","volume":"54","author":"GP Rossi","year":"2016","unstructured":"G.P. Rossi, G. Ceolotto, G. Rossitto, T.M. Seccia, G. Maiolino, C. Berton et al. Prospective validation of an automated chemiluminescence-based assay of renin and aldosterone for the work-up of arterial hypertension. Clin. Chem. Lab. Med. 54, 1441\u20131450 (2016). https:\/\/doi.org\/10.1515\/CCLM-2015-1094","journal-title":"Clin. Chem. Lab. Med."},{"key":"3573_CR43","doi-asserted-by":"publisher","first-page":"1261","DOI":"10.1210\/JCEM-26-11-1261","volume":"26","author":"LK Wolfe","year":"1966","unstructured":"L.K. Wolfe, R.D. Gordon, D.P. Island, G.W. Liddle, An analysis of factors determining the circadian pattern of aldosterone excretion. J. Clin. Endocrinol. Metab. 26, 1261\u20131266 (1966). https:\/\/doi.org\/10.1210\/JCEM-26-11-1261","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR44","doi-asserted-by":"publisher","unstructured":"M. Stowasser, A.H. Ahmed, E. Pimenta, P.J. Taylor, R.D. Gordon, Factors affecting the aldosterone\/renin ratio. Horm. Metab. Res. 44 (2012) https:\/\/doi.org\/10.1055\/s-0031-1295460","DOI":"10.1055\/s-0031-1295460"},{"key":"3573_CR45","doi-asserted-by":"publisher","first-page":"891","DOI":"10.1161\/HYPERTENSIONAHA.120.16429","volume":"77","author":"N Yozamp","year":"2021","unstructured":"N. Yozamp, G.L. Hundemer, M. Moussa, J. Underhill, T. Fudim, B. Sacks et al. Intraindividual Variability of Aldosterone Concentrations in Primary Aldosteronism: Implications for Case Detection. Hypertens. (Dallas, Tex. 1979) 77, 891\u2013899 (2021). https:\/\/doi.org\/10.1161\/HYPERTENSIONAHA.120.16429","journal-title":"Hypertens. (Dallas, Tex. 1979)"},{"key":"3573_CR46","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1210\/jc.2002-021476","volume":"88","author":"A Tanabe","year":"2003","unstructured":"A. Tanabe, M. Naruse, S. Takagi, K. Tsuchiya, T. Imaki, K. Takano, Variability in the renin\/aldosterone profile under random and standardized sampling conditions in primary aldosteronism. J. Clin. Endocrinol. Metab. 88, 2489\u20132494 (2003). https:\/\/doi.org\/10.1210\/jc.2002-021476","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR47","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1007\/S12020-022-03029-4","volume":"76","author":"M Araujo-Castro","year":"2022","unstructured":"M. Araujo-Castro, M. Paja Fano, M. Gonz\u00e1lez Boillos, B. Pla Peris, E. Pascual-Corrales, A.M. Garc\u00eda Cano et al. Evolution of the cardiometabolic profile of primary hyperaldosteronism patients treated with adrenalectomy and with mineralocorticoid receptor antagonists: results from the SPAIN-ALDO Registry. Endocrine 76, 687\u2013696 (2022). https:\/\/doi.org\/10.1007\/S12020-022-03029-4","journal-title":"Endocrine"},{"key":"3573_CR48","doi-asserted-by":"publisher","unstructured":"R. Libianto, M. Stowasser, G. Russell, P.J. Fuller, J. Yang, Improving Detection Rates for Primary Aldosteronism. Exp. Clin. Endocrinol. Diabetes (2023) https:\/\/doi.org\/10.1055\/A-2048-6213","DOI":"10.1055\/A-2048-6213"},{"key":"3573_CR49","doi-asserted-by":"publisher","unstructured":"E. Ng, S.M. Gwini, W. Zheng, P.J. Fuller, J. Yang, Predicting bilateral subtypes of primary aldosteronism without adrenal vein sampling: a systematic review and meta-analysis. J. Clin. Endocrinol. Metab. (2023) https:\/\/doi.org\/10.1210\/CLINEM\/DGAD451","DOI":"10.1210\/CLINEM\/DGAD451"},{"key":"3573_CR50","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1507\/ENDOCRJ.EJ11-0133","volume":"58","author":"T Nishikawa","year":"2011","unstructured":"T. Nishikawa, M. Omura, F. Satoh, H. Shibata, K. Takahashi, N. Tamura et al. Guidelines for the diagnosis and treatment of primary aldosteronism-the Japan Endocrine Society 2009. Endocr. J. 58, 711\u2013721 (2011). https:\/\/doi.org\/10.1507\/ENDOCRJ.EJ11-0133","journal-title":"Endocr. J."},{"key":"3573_CR51","doi-asserted-by":"publisher","first-page":"308","DOI":"10.1111\/CEN.13757","volume":"89","author":"H Hashimura","year":"2018","unstructured":"H. Hashimura, J. Shen, P.J. Fuller, N.Y.N. Chee, J.C.G. Doery, W. Chong et al. Saline suppression test parameters may predict bilateral subtypes of primary aldosteronism. Clin. Endocrinol. (Oxf.) 89, 308\u2013313 (2018). https:\/\/doi.org\/10.1111\/CEN.13757","journal-title":"Clin. Endocrinol. (Oxf.)"},{"key":"3573_CR52","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1507\/ENDOCRJ.EJ20-0329","volume":"68","author":"N Wada","year":"2021","unstructured":"N. Wada, A. Miyoshi, H. Usubuchi, S. Terae, Y. Shibayama, B. Takahashi et al. Prediction of unilateral hyperaldosteronism on adrenal vein sampling using captopril challenge test in patients with primary aldosteronism. Endocr. J. 68, 45\u201351 (2021). https:\/\/doi.org\/10.1507\/ENDOCRJ.EJ20-0329","journal-title":"Endocr. J."},{"key":"3573_CR53","doi-asserted-by":"publisher","unstructured":"T. Kocjan, G. Vidmar, P. Popovi\u0107, M. Stankovi\u0107, Validation of three novel clinical prediction tools for primary aldosteronism subtyping. Endocr Connect 2022;11 https:\/\/doi.org\/10.1530\/EC-21-0532","DOI":"10.1530\/EC-21-0532"},{"key":"3573_CR54","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1210\/jc.2011-1537","volume":"97","author":"TJ Burton","year":"2012","unstructured":"T.J. Burton, I.S. Mackenzie, K. Balan, B. Koo, N. Bird, D.V. Soloviev et al. Evaluation of the sensitivity and specificity of 11C-metomidate positron emission tomography (PET)-CT for lateralizing aldosterone secretion by Conn\u2019s adenomas. J. Clin. Endocrinol. Metab. 97, 100\u2013109 (2012). https:\/\/doi.org\/10.1210\/jc.2011-1537","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR55","doi-asserted-by":"publisher","first-page":"1226","DOI":"10.1097\/MNM.0000000000001293","volume":"41","author":"A Saiga","year":"2020","unstructured":"A. Saiga, H. Yokota, H. Nagano, K. Sawada, Y. Kubota, T. Wada et al. 131I-6\u03b2-iodomethyl-19-norcholesterol adrenal scintigraphy as an alternative to adrenal venous sampling in differentiating aldosterone-producing adenoma from bilateral idiopathic hyperaldosteronism. Nucl. Med. Commun. 41, 1226\u20131233 (2020). https:\/\/doi.org\/10.1097\/MNM.0000000000001293","journal-title":"Nucl. Med. Commun."},{"key":"3573_CR56","doi-asserted-by":"publisher","first-page":"1934","DOI":"10.3390\/BIOMEDICINES11071934","volume":"11","author":"M Araujo-Castro","year":"2023","unstructured":"M. Araujo-Castro, M. Paja Fano, M. Gonz\u00e1lez Boillos, E. Pascual-Corrales, A.M. Garc\u00eda Cano, P. Parra Ram\u00edrez et al. Diagnostic Accuracy of Adrenal Iodine-131 6-Beta-Iodomethyl-19-Norcholesterol Scintigraphy for the Subtyping of Primary Aldosteronism. Biomedicines 11, 1934 (2023). https:\/\/doi.org\/10.3390\/BIOMEDICINES11071934","journal-title":"Biomedicines"},{"key":"3573_CR57","doi-asserted-by":"publisher","first-page":"1929","DOI":"10.1097\/HJH.0000000000002520","volume":"38","author":"P Mulatero","year":"2020","unstructured":"P. Mulatero, L.A. Sechi, T.A. Williams, J.W.M. Lenders, M. Reincke, F. Satoh et al. Subtype diagnosis, treatment, complications and outcomes of primary aldosteronism and future direction of research: a position statement and consensus of the Working Group on Endocrine Hypertension of the European Society of Hypertension. J. Hypertens. 38, 1929\u20131936 (2020). https:\/\/doi.org\/10.1097\/HJH.0000000000002520","journal-title":"J. Hypertens."},{"key":"3573_CR58","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1007\/S12020-022-03122-8","volume":"78","author":"M Araujo-Castro","year":"2022","unstructured":"M. Araujo-Castro, M. Paja Fano, M. Gonz\u00e1lez Boillos, B. Pla Peris, E. Pascual-Corrales, A.M. Garc\u00eda Cano et al. Adrenal venous sampling in primary aldosteronism: Experience of a Spanish multicentric study (Results from the SPAIN-ALDO Register). Endocrine 78, 363\u2013372 (2022). https:\/\/doi.org\/10.1007\/S12020-022-03122-8","journal-title":"Endocrine"},{"key":"3573_CR59","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/S2213-8587(14)70069-5","volume":"3","author":"S Monticone","year":"2015","unstructured":"S. Monticone, A. Viola, D. Rossato, F. Veglio, M. Reincke, C. Gomez-Sanchez et al. Adrenal vein sampling in primary aldosteronism: towards a standardised protocol. Lancet Diabetes Endocrinol. 3, 296\u2013303 (2015). https:\/\/doi.org\/10.1016\/S2213-8587(14)70069-5","journal-title":"Lancet Diabetes Endocrinol."},{"key":"3573_CR60","doi-asserted-by":"publisher","first-page":"487","DOI":"10.1210\/jc.2018-01299","volume":"104","author":"AT Nanba","year":"2018","unstructured":"A.T. Nanba, T. Wannachalee, J.J. Shields, J.B. Byrd, W.E. Rainey, R.J. Auchus et al. Adrenal Vein Sampling Lateralization Despite Mineralocorticoid Receptor Antagonists Exposure in Primary Aldosteronism. J. Clin. Endocrinol. Metab. 104, 487\u2013492 (2018). https:\/\/doi.org\/10.1210\/jc.2018-01299","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR61","doi-asserted-by":"publisher","first-page":"4397","DOI":"10.1210\/jc.2014-2788","volume":"99","author":"M Haase","year":"2014","unstructured":"M. Haase, A. Riester, P. Kr\u00f6pil, S. Hahner, C. Degenhart, H.S. Willenberg et al. Outcome of adrenal vein sampling performed during concurrent mineralocorticoid receptor antagonist therapy. J. Clin. Endocrinol. Metab. 99, 4397\u20134402 (2014). https:\/\/doi.org\/10.1210\/jc.2014-2788","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"3573_CR62","doi-asserted-by":"publisher","unstructured":"G.P. Rossi, G. Maiolino, T.M. Seccia, R. GP, M. G, S. TM Adrenal Venous Sampling: Where Do We Stand? Endocrinol. Metab. Clin. North Am. 48, (2019) https:\/\/doi.org\/10.1016\/j.ecl.2019.08.012.","DOI":"10.1016\/j.ecl.2019.08.012"},{"key":"3573_CR63","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1097\/HJH.0000000000002453","volume":"38","author":"T Unger","year":"2020","unstructured":"T. Unger, C. Borghi, F. Charchar, N.A. Khan, N.R. Poulter, D. Prabhakaran et al. 2020 International Society of Hypertension global hypertension practice guidelines. J. Hypertens. 38, 982\u20131004 (2020). https:\/\/doi.org\/10.1097\/HJH.0000000000002453","journal-title":"J. Hypertens."}],"container-title":["Endocrine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12020-023-03573-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12020-023-03573-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,29]],"date-time":"2024-02-29T02:16:05Z","timestamp":1709172965000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12020-023-03573-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,26]]},"references-count":63,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,3]]}},"alternative-id":["3573"],"URL":"https:\/\/doi.org\/10.1007\/s12020-023-03573-7","relation":{},"ISSN":["1559-0100"],"issn-type":[{"value":"1559-0100","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,26]]},"assertion":[{"value":"31 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 October 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}